Mizuho lowers Haemonetics stock price target to $70 on VASCADE MVP slowdown

Haemonetics (HAE) reported strong fiscal Q1 2026 results, exceeding revenue and EPS expectations, yet its stock plummeted 26% on Thursday. The sharp decline was driven by a significant deceleration in its key VASCADE MVP product line, with growth slowing to 6% from 28% due to internal strategy and competitive pressures. This slowdown prompted Mizuho to lower its price target to $70 from $90 and other firms like Raymond James and JPMorgan to downgrade the stock, highlighting investor and analyst concerns over future growth prospects despite current strong fundamentals.

Analysis

Haemonetics (HAE) presents a clear case of market focus on future growth over past performance, with its stock falling 26% despite reporting fiscal first-quarter results that beat consensus expectations. The company exceeded revenue forecasts by $20 million, reaching $321 million, and surpassed EPS estimates by $0.09 with a reported $1.10. This strong performance was driven by outperformance in its Plasma and Blood Center divisions. However, the severe market reaction was triggered by a critical deceleration in its VASCADE MVP product line, where growth plummeted from 28% in the prior quarter to just 6%. This slowdown is attributed to a combination of internal strategy issues, specifically a prior focus on new account acquisition over existing account penetration, and external competitive pressures from private companies offering free samples. Consequently, multiple analysts have revised their outlooks; Mizuho lowered its price target to $70 from $90, projecting a recovery period of at least six months, while Raymond James and JPMorgan downgraded the stock, citing the slowdown and mixed performance. The market is thus pricing in significant uncertainty surrounding the recovery of a key growth driver, overshadowing the otherwise solid fundamentals and strong results from other business segments.

Key Decisions for Investors

• Investors should closely monitor management's commentary and future quarterly reports for signs of stabilization or recovery in the VASCADE MVP product line, as its performance is the central driver of current market sentiment.
• Given the 26% stock price decline, investors must weigh the company's apparently discounted valuation and strong performance in its Plasma division against the significant uncertainty and competitive headwinds facing its high-growth Hospital segment.
• The wave of analyst downgrades from firms like Mizuho, Raymond James, and JPMorgan signals a deteriorated near-term outlook, suggesting caution is warranted until a clear turnaround strategy for the VASCADE slowdown is demonstrated and proves effective.